Search Clinical Trials
Sponsor Condition of Interest |
---|
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive...
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant)
to using binimetinib plus the usual treatment in patients with hormone receptor positive
breast cancer that has spread from where it first started to other places in the body
(metastatic) and has an NF1 genetic... expand
This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone. Type: Interventional Start Date: Sep 2024 |
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric...
Nationwide Children's Hospital
Neuroblastoma
Sarcoma
This study will expand the types of pediatric cancers being evaluated for response to
cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma,
rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will
extend this evaluation to tumors that have... expand
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted. The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure. Type: Interventional Start Date: Jul 2022 |
Olorofim Aspergillus Infection Study
F2G Biotech GmbH
Invasive Aspergillosis
The purpose of this study is to compare treatment with olorofim versus treatment with
AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or
probable lower respiratory tract disease Aspergillus species (invasive aspergillosis,
IA). expand
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA). Type: Interventional Start Date: Mar 2022 |
INSPIRE Pipeline™ Shield Post Approval Study
Medtronic Neurovascular Clinical Affairs
Intracranial Aneurysm
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post
Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients
undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex
Embolization Device with Shield Technology™ ("Pipeline™... expand
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States. Type: Observational [Patient Registry] Start Date: Dec 2021 |
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures At High Risk of...
Major Extremity Trauma Research Consortium
Post Operative Surgical Site Infection
The overall objective is to compare the effect of Vancomycin and Tobramycin powder
combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation
infections of tibial plateau and tibial pilon fractures at high risk of infection
(collectively considered the "study injuries"). expand
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries"). Type: Interventional Start Date: May 2021 |
Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal...
National Institute of Allergy and Infectious Diseases (NIAID)
Gonococcal Infection
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of
the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and
women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae
infection. Approximately 2,200 participants... expand
This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least 202 evaluable participants. Data will be collected in an observer-blind manner. Study product recipients and study staff responsible for the evaluation of any study endpoint will be unaware of whether Bexsero or placebo were administered. The duration of the study for participants who are enrolled and randomized will be approximately 16 months. Study participation is expected to be completed in approximately 36 months. The primary objective of the study is to demonstrate efficacy of Bexsero in prevention of urogenital and/or anorectal gonococcal infection. Type: Interventional Start Date: Dec 2020 |
Rare CFTR Mutation Cell Collection Protocol (RARE)
George Solomon
Cystic Fibrosis
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance
regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential
therapies that directly target defective CFTR are being evaluated in important clinical
trials, but most target the most common CFTR... expand
Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target defective CFTR are being evaluated in important clinical trials, but most target the most common CFTR mutation F508del. Many patients with rare CF mutations are not able to participate in those studies. The RARE study is specifically designed for people with CF caused by rare mutations. Eligible rare mutations are listed below: • CF patients who are heterozygous for pre-mature stop codons as noted below: i. one allele must be a F508del ii. the other allele must be a pre-mature stop codon mutation • CF Patients with other genotypes that require Study PI permission: i. CF patients with two mutations that are not eligible for Trikafta ii. CF patients homozygous or heterozygous (other allele must be F508del) for rare mutations of special interest (e.g., 711+3A->G, 2789+5G->A, 3272-26A->G, 3849+10kbC->T). Other rare mutations will be considered on a case by case basis This is a multi-site, specimen collection study. Investigators will collect blood, intestinal cells and nasal cells from each participant. Cells from these specimens will be used to test future CFTR modulators to see if they might work for people with study eligible rare mutations. Having cells to test in the lab is an important first step in identifying potential new therapies for people with these mutations. Type: Observational Start Date: Oct 2017 |
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients
with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may
have spread from where it first... expand
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Type: Interventional Start Date: Nov 2015 |
Evaluation of Free Gingival Graft Timing
University of Alabama at Birmingham
Ridge Augmentation
Alveolar Mucosa
This clinical trial aims to compare and evaluate the clinical outcomes between two
distinct treatment sequences: free gingival graft surgery preceding guided bone
regeneration and guided bone regeneration followed by free gingival graft. expand
This clinical trial aims to compare and evaluate the clinical outcomes between two distinct treatment sequences: free gingival graft surgery preceding guided bone regeneration and guided bone regeneration followed by free gingival graft. Type: Interventional Start Date: Aug 2024 |
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized...
University of Alabama at Birmingham
Human Papilloma Virus
To determine if the emergency department (ED) setting offers a viable space for improving
HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human
papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study
will develop, pilot and evaluate... expand
To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it may be recommended under shared decision making, SDM). Type: Observational Start Date: Aug 2024 |
Enlighten Study: The EV-ICD Post Approval Registry
Medtronic
Ventricular Arrhythmia
Tachycardia
Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm
safety and effectiveness of EV-ICD in routine clinical practice, following commercial
release of EV-ICD devices. expand
Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm safety and effectiveness of EV-ICD in routine clinical practice, following commercial release of EV-ICD devices. Type: Observational Start Date: Sep 2023 |
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults with HIV
University of Alabama at Birmingham
HIV
Arterial Stiffness
Cognitive Dysfunction
This is a single site, randomized exercise trial with individuals at least 50 years of
age living with HIV who experience suboptimal cognition. The overall goals of this
proposal are to determine whether 16 weeks of structured high-intensity interval training
(HIIT) can overcome vascular and cognitive... expand
This is a single site, randomized exercise trial with individuals at least 50 years of age living with HIV who experience suboptimal cognition. The overall goals of this proposal are to determine whether 16 weeks of structured high-intensity interval training (HIIT) can overcome vascular and cognitive impairments (Aim 1) to a greater extent than continuous moderate exercise. Additionally, investigator will seek to identify barriers to engagement in exercise and the participants' perceptions of the study and exercise interventions (Aim 2). This study will enroll 60 participants in Birmingham, Alabama. Data collection will occur at each visit, with baseline data collected at the initial visit with a 3-month follow-up occurring following completion of the intervention. Type: Interventional Start Date: Feb 2024 |
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy...
ECOG-ACRIN Cancer Research Group
Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Liver
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in
addition to standard of care chemotherapy versus standard of care chemotherapy alone in
treating patients with colorectal cancer that has spread to the liver (liver metastases)
and cannot be removed by surgery (unresectable).... expand
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases. Type: Interventional Start Date: Oct 2023 |
A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple...
Gracell Biopharmaceuticals, Inc.
Relapsed/ Refractory Multiple Myeloma
This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual
CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma. expand
This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma. Type: Interventional Start Date: Jul 2023 |
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Chris Goss
Cystic Fibrosis
Cystic Fibrosis Pulmonary Exacerbation
The purpose of this study is to look at pulmonary exacerbations in people with cystic
fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into
a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory
symptoms in people with CF that needs medical... expand
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonary exacerbation: - Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two different types of antibiotics (tobramycin and β-lactams)? - Is taking one type of antibiotic just as good as taking two types? Type: Interventional Start Date: Apr 2023 |
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic...
Takeda
Pancreatic Cancer
Hepatocellular Cancer
Mesothelioma
Breast Cancer
Gastric Cancer
This study is about TAK-500, given either alone or with pembrolizumab, in adults with
select locally advanced or metastatic solid tumors.
The aims of the study are:
- to assess the safety profile of TAK-500 when given alone and when given with
pembrolizumab.
- to assess the anti-tumor... expand
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: - to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. - to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment. Type: Interventional Start Date: Apr 2022 |
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
Yale University
Deep Venous Thrombosis
The goal of the CRETE Studies is to investigate the newly identified age-dependent
heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous
catheter-associated deep venous thrombosis in critically ill children. expand
The goal of the CRETE Studies is to investigate the newly identified age-dependent heterogeneity in the efficacy of enoxaparin in reducing the risk of central venous catheter-associated deep venous thrombosis in critically ill children. Type: Interventional Start Date: May 2022 |
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
Children's Hospital of Philadelphia
Juvenile Spondyloarthritis
This randomized pragmatic trial will generate knowledge about strategies used to
de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile
spondyloarthritis with sustained inactive disease and are treated at one of the 29
participating pediatric healthcare systems. This... expand
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms. Type: Interventional Start Date: Nov 2021 |
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients...
Boehringer Ingelheim
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
This study is open to adults with advanced solid tumors whose previous cancer treatment
was not successful. People can participate if their tumor has the B7-H6 marker or if they
have colorectal cancer.
The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines
may... expand
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines may help the immune system fight cancer. The purpose of this study is to find out the highest dose of BI 765049 alone and in combination with ezabenlimab the participants can tolerate. In this study, BI 765049 is given to people for the first time. Participants can stay in the study for up to 3 years, if they benefit from treatment and can tolerate it. During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. The doctors also regularly monitor the size of the tumor. Type: Interventional Start Date: May 2021 |
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab...
Novartis Pharmaceuticals
Sickle Cell Disease
This is a multi-center multi-national rollover study to allow continued access to
crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab
treatment in a Novartis-sponsored study (parent study) and are benefiting from the
treatment as judged by the investigator. expand
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator. Type: Interventional Start Date: Jun 2021 |
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Advanced Cancer
Metastatic Cancer
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
This clinical trial is evaluating a drug called ART0380 in participants with advanced or
metastatic solid tumors. The main goals of this study are to:
- Find the recommended dose of ART0380 that can be given safely to participants alone
and in combination with gemcitabine or irinotecan... expand
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: - Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan - Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan - Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan Type: Interventional Start Date: Dec 2020 |
Virtual Reality-Base Intelligent Orientation and Mobility Specialists Trial
University of Alabama at Birmingham
Low Vision, Both Eyes
The human subject research is a randomized, controlled training trial that tests the
effectiveness of three Virtual Reality-based Intelligent Orientation and Mobility
Specialists (VR-IOMSs) in teaching orientation and mobility (O&M) task skills to low
vision patients. It will be conducted on two sites,... expand
The human subject research is a randomized, controlled training trial that tests the effectiveness of three Virtual Reality-based Intelligent Orientation and Mobility Specialists (VR-IOMSs) in teaching orientation and mobility (O&M) task skills to low vision patients. It will be conducted on two sites, University of Alabama at Birmingham (UAB) and Alabama Institute for Deaf and Blind (AIDB). The same protocol will be used on both sites. UAB will be the sIRB for the trial. Three O&M tasks will be studied, timing to cross a signalized street using the near lane parallel traffic surge skill, timing to cross an uncontrolled street using the traffic gap judgment skill and learning outdoor numbering system. A VR-IOMS will be develop for each task. The training does not involve research subjects walking into street traffic. Low vision subjects who have difficulties with these O&M tasks due to their impaired vision will be randomized into three groups, learning the task from a VR-IOMS (experimental group), from a human Certified Orientation & Mobility Specialist (COMS) in real streets (active control group) and not learning the task but spending the same amount of time watching low vision education videos (placebo group). All subjects will be evaluated by COMSs in real streets around the two study sites before training (pre-training), within 3 days after the completion of training (post-training) and 3 months after the completion of training (follow up). Their ability to perform the O&M tasks will be assess quantitatively using objective methods. COMSs who conduct these evaluations will be blinded for subject training assignment. The primary outcome measure is the training effect, the difference in task performance between the pre-training and post-training real street evaluations. The training effects of the 3 groups will be compared to determine the training effectiveness of the VR-IOMS relative to human COMS. Secondary outcome measures include the retainment of the training effect. Objective assessment of the VR-IOMS training process and trainee subjective evaluation of the VR-IOMS training will also be analyzed. Type: Interventional Start Date: Aug 2023 |
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
University of Utah
Autoimmune Encephalitis
Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line"
immunomodulatory therapies provided as standard-of-care, and either inebilizumab
(investigational agent) or placebo. expand
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Type: Interventional Start Date: Mar 2022 |
NTX-301 in MDS/AML
University of Alabama at Birmingham
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has
shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301
in patients with myeloid malignancies. expand
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies. Type: Interventional Start Date: Jan 2021 |
The Biosonographic Index
University of Alabama at Birmingham
Acute Kidney Injury
In this exploratory study we explore the use of Shear Wave Elastography to differentiate
between Acute Kidney Injury after vascular surgery and among the healthy population. expand
In this exploratory study we explore the use of Shear Wave Elastography to differentiate between Acute Kidney Injury after vascular surgery and among the healthy population. Type: Interventional Start Date: Jan 2020 |
- Previous
- Next